Stockholm 25 February, 2026 The Department of Medicine Solna at Karolinska Institutet and TikoMed AB have signed a letter of intent for a collaboration on a clinical study of ILB® in myocardial infarction. The study is called ILBIAMI and the aim is to evaluate the effect of ILB® in counteracting the consequences of myocardial infarction … Läs mer
News
TikoMed’s Board of Directors has appointed Dr Björn Pilström as Chief Executive Officer of TikoMed. Dr Pilström has an MD from Karolinska Institutet in Stockholm and a PhD in Immunology from Stockholm University. He has more than 25 years’ global experience from commercial, medical and managerial roles in the life science industry. The former CEO … Läs mer
Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind randomized phase where patients will get either Riluzole or ILB®, followed by a 6-month open-label extension where patients will get both ILB® and Riluzole. The study is sponsored by Oslo University Hospital, funded by public … Läs mer
At the Annual General Meeting on 30 June 2025, TikoMed elected a new board of directors for the period until the next general meeting. The three members of the interim board elected in April this year will continue their assignments – Göran Groth as Chairman of the Board and Tobhias Brandell and Lars Bruce as … Läs mer
Vid den ordinarie bolagsstämman den 30 juni 2025 valde TikoMed en ny styrelse för tiden fram till nästa bolagsstämma. De tre ledamöterna från interimsstyrelsen som valdes i april månad fortsätter sina uppdrag – Göran Groth som styrelseordförande och Tobhias Brandell och Lars Bruce som styrelseledamöter. Utöver dessa valde stämman in två nya styrelseledamöter – Anders … Läs mer
Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB® is safe and well tolerated in patients with ALS. Eleven patients participated in the prospective, single-arm, open-label, phase II clinical trial encompassing … Läs mer
Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic Lateral Sclerosis – ALS. TikoMed … Läs mer
Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board. Adriano Chiò is a neurologist currently working in Torino, Italy. … Läs mer
Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed Scientific Advisory Board. Professor Shefner … Läs mer
Viken – September 26, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Caroline Ingre, MD, PhD senior consultant neurology and Head of ALS at Karolinska University Hospital and Karolinska Institute as the second member of its newly-formed Scientific Advisory Board. Dr. Ingre runs the ALS clinic at Karolinska University Hospital and has … Läs mer